ZALTRAP 100 mg/4mL (Ziv-Aflibercept SOLUTION, CONCENTRATE) 100 mg/4mL

Ziv-aflibercept is an intravenous solution used in cancer treatment. This 100 mg/4mL concentrate is designed for medical professionals to administer under controlled conditions.

Strength

100 mg/4mL

Pack Size

1 VIAL in 1 CARTON (0024-5840-01) / 4 mL in 1 VIAL

Manufacturer / TM Owner

sanofi-aventis U.S. LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ziv-aflibercept is primarily used in combination with other cancer treatments. It works by targeting specific proteins involved in tumor growth and blood vessel formation. This medication is often used in the treatment of metastatic colorectal cancer, among other indications.

Side Effects

Common effects of ziv-aflibercept may include fatigue, diarrhea, and high blood pressure. Some patients may also experience appetite loss and protein in the urine. These effects can vary depending on individual health conditions and treatment plans.

Precautions & Warnings

Ziv-aflibercept should be handled with care and administered by healthcare professionals. It is important to monitor patients for signs of infusion reactions or other adverse effects. Proper storage and handling procedures should be followed to maintain the integrity of the solution.

Avoid Interactions

Ziv-aflibercept may interact with other medications, including those that affect blood pressure or blood clotting. It is important to inform healthcare providers about all current medications to avoid potential interactions. Alcohol and certain supplements may also affect the efficacy of ziv-aflibercept.

References

Frequently Asked Questions

Ziv-aflibercept is used in combination with other cancer treatments to target specific proteins involved in tumor growth and blood vessel formation.

Ziv-aflibercept is administered intravenously by healthcare professionals in a controlled medical setting.

Common side effects may include fatigue, diarrhea, high blood pressure, appetite loss, and protein in the urine.

Ziv-aflibercept may interact with other medications, so it is important to consult a healthcare provider before combining it with other treatments.

Ziv-aflibercept should be handled and administered by healthcare professionals, with monitoring for infusion reactions and other adverse effects.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.